Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 1816 AL 1830

Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease

Ding X, Chen Y, Zhang X, Duan Y, Yuan G, Liu C.

Neuropeptides. 2024 Oct;107:102457. doi: 10.1016/j.npep.2024.102457. Epub 2024 Jul 25.

Rodent Models of Alzheimer's Disease: Past Misconceptions and Future Prospects

Collins HM, Greenfield S.

Int J Mol Sci. 2024 Jun 5;25(11):6222. doi: 10.3390/ijms25116222.

ApoE: The Non-Protagonist Actor in Neurological Diseases

Grimaldi L, Bovi E, Formisano R, Sancesario G.

Genes (Basel). 2024 Oct 30;15(11):1397. doi: 10.3390/genes15111397.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease

McDowall S, Bagda V, Hodgetts S, Mastaglia F, Li D.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

Hölscher C.

Neuropharmacology. 2024 Aug 1;253:109952. doi: 10.1016/j.neuropharm.2024.109952. Epub 2024 Apr 25.

Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy

Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou JR.

Epigenomics. 2024 Jan;16(1):57-77. doi: 10.2217/epi-2023-0342. Epub 2023 Dec 13.

Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease

Hong CT, Chen JH, Hu CJ.

J Biomed Sci. 2024 Nov 5;31(1):102. doi: 10.1186/s12929-024-01090-x.

C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease

Yao Q, Long C, Yi P, Zhang G, Wan W, Rao X, Ying J, Liang W, Hua F.

CNS Neurosci Ther. 2024 Apr;30(4):e14721. doi: 10.1111/cns.14721.

The VEGFs/VEGFRs system in Alzheimer's and Parkinson's diseases: Pathophysiological roles and therapeutic implications

Ceci C, Lacal PM, Barbaccia ML, Mercuri NB, Graziani G, Ledonne A.

Pharmacol Res. 2024 Mar;201:107101. doi: 10.1016/j.phrs.2024.107101. Epub 2024 Feb 7.

Limonin (LM) and its derivatives: Unveiling the neuroprotective and anti-inflammatory potential of LM and V-A-4 in the management of Alzheimer's disease and Parkinson's disease

Panda SP, Kesharwani A, Singh M, Kumar S, Mayank, Mallick SP, Guru A.

Fitoterapia. 2024 Oct;178:106173. doi: 10.1016/j.fitote.2024.106173. Epub 2024 Aug 6.

The Olfactory Trail of Neurodegenerative Diseases

Franco R, Garrigós C, Lillo J.

Cells. 2024 Apr 2;13(7):615. doi: 10.3390/cells13070615.

Long Non-Coding RNAs: New Insights in Neurodegenerative Diseases

Anilkumar AK, Vij P, Lopez S, Leslie SM, Doxtater K, Khan MM, Yallapu MM, Chauhan SC, Maestre GE, Tripathi MK.

Int J Mol Sci. 2024 Feb 14;25(4):2268. doi: 10.3390/ijms25042268.

Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection

Chiang MC, Yang YP, Nicol CJB, Wang CJ.

Int J Mol Sci. 2024 Feb 17;25(4):2360. doi: 10.3390/ijms25042360.

Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases

Iyer S, Bhat I, Bangera Sheshappa M.

Mol Nutr Food Res. 2024 Jul;68(13):e2300409. doi: 10.1002/mnfr.202300409. Epub 2024 Mar 15.

Biomarkers for Managing Neurodegenerative Diseases

Cheslow L, Snook AE, Waldman SA.

Biomolecules. 2024 Mar 26;14(4):398. doi: 10.3390/biom14040398.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias